Chloroquine/dalteparin sodium/hydroxycarbamide: Prolongation of the QTc interval secondary to off-label use and lack of efficacy: case report

類似資料

• Multiple drugs: QTc prolongation, lack of efficacy and off-label use: 3 case reports
  出版事項: (2021)
• Chloroquine/lopinavir/ritonavir/umifenovir: QTc interval prolongation, drug interaction and off-label use: 2 case reports
  出版事項: (2020)
• Hydroxychloroquine: Prolonged QTc interval following off-label use: case report
  出版事項: (2020)
• QTc interval prolongation, COVID-19 and chloroquine
  著者:: Wiwanitkit, V.
  出版事項: (2020)
• Gilteritinib/hydroxycarbamide/remdesivir: Neutropenia, lack of efficacy and off-label use: case report
  出版事項: (2021)